Further functional assays conducted in an immunocompetent setting, both ex vivo and in vivo, demonstrated that HDAC6 inhibition sensitized murine myeloid leukemia cells to broad CD8<sup>+</sup> T cell activation as evidenced by increased TNFα and CD107a expression. The gene discussed is HDAC6; the disease is myeloid leukemia.